CC
PMVP icon

Centiva Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Centiva Capital’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-76,963
Closed -$125K – 2501
2024
Q2 		$125K Buy
+76,963
New +$139K ﹤0.01% 1811
2023
Q2 		– Sell
-25,711
Closed -$123K – 1919
2023
Q1 		$123K Buy
+25,711
New +$181K ﹤0.01% 1323

Other funds holding PMVP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Centiva Capital's PMVP Position: Q3 2024 in Review

Centiva Capital sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 76,963 shares — an estimated $125K sold.

Centiva Capital first reported a position in PMVP in Q1 2023 and held it in 2 quarters. The position peaked at $125K in Q2 2024. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

  • Centiva Capital reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 76,963 PMV Pharmaceuticals shares in Q3 2024, an estimated $125K.
  • Centiva Capital first reported a position in PMV Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Centiva Capital's PMV Pharmaceuticals position peaked at $125K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.